The Business of Biofabrication

More than 500 million people worldwide live with osteoarthritis, a degenerative joint disease that progressively destroys cartilage and bone until the joint is no longer functional. Current treatment endpoints, anti-inflammatory drugs, steroid injections, and eventual joint replacement surgery, address the symptoms of that destruction rather than reversing it. The Advanced Research Projects Agency for Health (ARPA-H) is now funding a serious attempt to change that, and the approach it is backing sits squarely at the intersection of regenerative medicine and biofabrication.

The NITRO Program

ARPA-H’s Novel Innovations for Tissue Regeneration in Osteoarthritis, known as NITRO, is structured around three distinct technical areas that together form a full clinical spectrum of intervention, from early-stage joint repair to complete joint replacement using biological materials.

Technical Area 1 targets injectable and non-invasive bone regeneration. Technical Area 2 targets injectable and non-invasive cartilage regeneration. Technical Area 3, the most ambitious, targets the development of replacement joints built from a patient’s own human cells, designed to be load-bearing, non-immunogenic, and fixed without permanent hardware such as plates or screws.

The program has awarded funding to multidisciplinary teams across institutions including Duke University, Washington University in St. Louis, University of Colorado Boulder, Columbia University, and Case Western Reserve University. Phase 1 clinical trials of the first NITRO therapies are anticipated by 2028.

What the CU Boulder Team Has Built

The most detailed recent results come from a team spanning the University of Colorado Boulder, CU Anschutz, and Colorado State University, working under an award of up to $33.5 million. The team has developed two complementary approaches.

The first is a single regenerative injection that, in animal studies, prompted arthritic joints to return to a healthy state within four to eight weeks. The second is a biomaterial repair kit designed to recruit the body’s own cells to patch holes in damaged cartilage, effectively turning the patient’s endogenous biology into the manufacturing process.

That second approach, using an engineered biomaterial to direct cellular behavior and drive tissue formation in situ, is a form of biofabrication without a printer. Rather than producing tissue constructs ex vivo and implanting them, it encodes the regenerative instruction into the material itself and allows the body to execute it. The distinction from classical tissue engineering is meaningful: the manufacturing happens inside the patient.

In early 2026, Renovare Therapeutics was formed to commercialize the portfolio of product candidates emerging from this NITRO work, signaling that the program has already generated IP and development assets mature enough to anchor a standalone company.

Technical Area 3 and the Biofabrication Connection

The most direct line to biofabrication runs through TA3. Columbia University’s team is focused on developing integrated total knee implants constructed from a patient’s own cells. These are not synthetic devices coated in biologics. They are joints built from human cellular material, designed to integrate with native bone and cartilage, bear physiological loads, and avoid immune rejection.

Building a load-bearing joint structure from human cells, one that can be implanted, fixed without hardware, and survive the mechanical demands of a knee, is an engineering challenge of a different order than building soft tissue constructs. It requires control over cell-material interactions, structural architecture, mechanical properties, and biological signaling simultaneously. It is, in practical terms, a biofabrication problem.

Whether the Columbia team is using bioprinting, molding, scaffold-seeding approaches, or some combination is not fully disclosed in public materials. But the output specification, a patient-specific, cell-derived joint that functions mechanically and biologically, is indistinguishable from what the most ambitious biofabrication programs in the world are working toward.

NITRO Inside ARPA-H’s Broader Biofabrication Strategy

NITRO does not exist in isolation within ARPA-H’s portfolio. The agency is simultaneously running PRINT, a program explicitly aimed at bioprinting universally matched organs on demand. The co-existence of NITRO and PRINT within the same agency’s active funding portfolio reflects a coherent federal view that regenerative medicine, across the spectrum from injectable biomaterials to full organ bioprinting, is a solvable engineering problem worth treating as a national priority.

This is the context in which the $280 million Canadian government partnership with Aspect Biosystems and comparable investments in Europe should be read. The US federal government, through ARPA-H, is making parallel bets at both the tissue and organ scale, and it is doing so with the operational urgency of a defense research agency rather than the multi-decade timelines of traditional NIH grant cycles.

What Still Has to Be Solved

The NITRO program is candid about the difficulty of what it is attempting. Cartilage is avascular, meaning it has no direct blood supply and heals poorly on its own, which is why osteoarthritis progresses as it does. Engineering constructs or materials that can stimulate durable cartilage regeneration, rather than fibrocartilage scar tissue, remains one of the hardest problems in musculoskeletal biology.

For TA3 specifically, demonstrating that a cell-derived joint can survive physiological loading over years rather than months, without resorting to the permanent fixation hardware that conventional implants require, is a claim that will need extensive long-term preclinical and clinical data before it can be made with confidence.

The 2028 clinical trial target is ambitious. Whether it holds will depend on how the preclinical data develops over the next 18 to 24 months and how regulators approach the novel device and biological classification questions these constructs will raise.

The Bigger Picture

ARPA-H’s bet on NITRO is, at its core, a bet that the biology of joint regeneration is now understood well enough, and the engineering tools now capable enough, to close the gap between what the body can do naturally and what it needs medicine to provide. The biofabrication sector has been making the same argument for a decade. The difference now is that the federal government is funding it on an ARPA timescale, with commercialization infrastructure already forming around the first wave of results.